Immunome Reports Second Quarter 2021 Financial Results
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently reported financial results for the second quarter ended June 30, 2021, and provided a corporate update.
Read MoreVariants of SARS-CoV-2
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing. Furthermore, IMM-BCP-01 showed …
Read More
Ocugen’s COVID-19 Vaccine Demonstrating 77.8% Protection
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from …
Read More Immunome Announces Additional $4.3 Million Award by DOD
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, announced a $4.3 …
Read More Immunome Reports First Quarter 2021 Financial Results
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, reported financial results …
Read More Ocugen’s COVAXIN Potentially Effective Against Three Key Variants of SARS-CoV-2
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, …
Read MoreFDA Authorizes Adaptive Biotechnologies T-Detect COVID Test
WASHINGTON, D.C. — The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a …
Read More
FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants
WASHINGTON, D.C. — The U.S. Food and Drug Administration this week issued guidance for medical product developers, specifically covering vaccines, diagnostics and therapeutics products, to address the emergence and potential …
Read More
Chester County-based Biopharmaceutical Company Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced that its discovery engine …
Read More
FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation
WASHINGTON, D.C. — The U.S. Food and Drug Administration has alerted clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including …
Read More